Crescens Tiu

Fulham Road
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma.

Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 24, 2025

Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy.

Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy.

Journal: Nature communications

Published: January 08, 2025

A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death.

A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death.

Journal: Immunity

Published: July 10, 2023

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.

Journal: Nature

Published: May 23, 2023

A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy.

A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy.

Journal: Journal of immunotherapy and precision oncology

Published: April 23, 2021

Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience.

Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience.

Journal: Cancer treatment and research communications

Published: December 03, 2020

Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective.

Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective.

Journal: Critical reviews in oncology/hematology

Published: November 23, 2020

A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic.

A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic.

Journal: The Lancet. Oncology

Published: May 21, 2020

Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials.

Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 10, 2020

Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials.

Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials.

Journal: Oncology

Published: May 21, 2019

Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers.

Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers.

Journal: Asia-Pacific journal of clinical oncology

Published: September 29, 2017

Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management.

Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management.

Journal: Asia-Pacific journal of clinical oncology

Published: January 11, 2015

Showing 1-12 of 12

Last Updated: 09/26/2026